PROTEINA is a platform biotech unlocking precision medicine through single-molecule protein–protein interaction analysis—advancing biomarker development and antibody optimization from early research to clinical translation.

We’re out-licensing a next-gen anti-TNFα antibody, optimized using our platform and validated in vivo with up to 100x lower dose.

PathFinder — our SPID™-powered biomarker platform detects PPI dynamics at femtomolar sensitivity across preclinical and clinical samples. Used by global pharmas for target engagement, dose selection, and efficacy assays.

Landscape — our high-throughput antibody optimization platform screens thousands of variants without purification, capturing affinity, productivity, stability, and more. Actively used for affinity maturation, CDR redesign, and developability profiling across novel and biosimilar programs.

From early development to clinical insight, PROTEINA delivers scalable, precision-driven solutions powered by protein interactions.